N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-nitroguanidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-nitroguanidine
• 英文别名: 2-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-nitroguanidine
• 化学式: C₁₁H₁₉N₅O₃S
• 分子量: 301.37
• InChiKey: SKFSGGYLFMBUNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-硝基-S-甲基异硫脲 、 2-(((5-二甲基氨基)甲基)-2-呋喃基)甲基)硫代乙胺 在 乙酸乙酯 、 petroleum ether 作用下， 以 乙醇 为溶剂， 反应 0.08h， 以to give N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-nitroguanidine m.p. 103°-104°的产率得到N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-nitroguanidine
  参考文献：
  名称：

  Aminoalkyl furan derivatives

  摘要：

  一般式I的化合物：##STR1##及其生理上可接受的盐和N-氧化物和水合物，其中R.sub.1和R.sub.2可以相同或不同，代表氢，低级烷基，环烷基，低级烯基，芳基烷基或被氧原子或基团##STR2##中断的低级烷基，在其中R.sub.4代表氢或低级烷基，或R.sub.1和R.sub.2可以与它们附着的氮原子一起形成一个杂环，该杂环可以包含从O和##STR3##选择的其他杂原子；R.sub.3是氢，低级烷基，低级烯基或烷氧基烷基；X是--CH.sub.2 --，O或S；Y代表.dbd. S，.dbd. O，.dbd. NR.sub.5或.dbd. CHR.sub.6；Alk表示1到6个碳原子的直链或支链烷基链；R.sub.5是H，硝基，氰基，低级烷基，芳基烷基，烷基磺酰基或芳基磺酰基；R.sub.6代表硝基，芳基磺酰基或烷基磺酰基；M是2到4的整数；N是1或2；或当X.dbd.S，或--CH.sub.2 --时，n为零，1或2。这些化合物具有H.sub.2-拮抗剂活性。还提供了其生产的中间体。

  公开号：

  US04128658A1

文献信息

• N'-Derivatives of N-(2-mercapto-ethyl)-2-nitro-1,1-ethenediamine
  申请人：Allen & Hansbury, Limited

  公开号：US04169855A1

  公开（公告）日：1979-10-02

  Compounds of the general formula: ##STR1## in which R.sub.3 is hydrogen, lower alkyl, lower alkenyl or alkoxyalkyl. These compounds are useful in the preparation of novel aminoalkyl furan derivatives having a selective action on histamine receptors.

  一般式为##STR1##的化合物，其中R.sub.3为氢、低级烷基、低级烯基或烷氧基烷基。这些化合物在制备具有对组胺受体选择性作用的新型氨基烷基呋喃衍生物中非常有用。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR
  申请人：Shahid Muslim D.

  公开号：US20150238463A1

  公开（公告）日：2015-08-27

  The present disclosure describes a treatment for acid related gastrointestinal disorders. The compounds described herein are known gastric acid secretion inhibitors in combination with alpha lipoic acid (ALA) or related compounds. ALA is not known as a treatment for acid related gastrointestinal disorders, however, ALA, when combined as described in the present disclosure with certain compounds used in the treatment of acid related gastrointestinal disorders, significantly improves existing treatments.
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR.
  申请人：Shahid Muslim D.

  公开号：US20160354342A1

  公开（公告）日：2016-12-08

  A treatment for acid related gastrointestinal disorders. The methods and compounds described include gastric acid secretion inhibitors in combination with alpha lipoic acid (ALA) or related compounds. ALA is not known as a treatment for acid related gastrointestinal disorders; however, when combined with certain compounds used in the treatment of acid related gastrointestinal disorders, ALA significantly improves existing treatments.
• US4128658A
  申请人：——

  公开号：US4128658A

  公开（公告）日：1978-12-05
• US4169855A
  申请人：——

  公开号：US4169855A

  公开（公告）日：1979-10-02